

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see **DOSAGE AND ADMINISTRATION**).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Twenty-five pediatric patients ages 6 to 12 years, with atopic dermatitis, were enrolled in an open-label, hypothalamic-pituitary-adrenal (HPA) axis safety study. Betamethasone dipropionate lotion 0.05% was applied twice daily for 2 to 3 weeks over a mean body surface area of 45% (range 35% to 72%). In 11 of 15 (73%) evaluable patients, adrenal suppression was indicated by either a ≤ 5 mcg/dL pre-stimulation cortisol, or a cosyntropin post-stimulation cortisol ≤ 18 mcg/dL and an increase of < 7 mcg/dL from the baseline cortisol. Studies performed with betamethasone dipropionate lotion 0.05% indicate that it is in the medium range of potency as compared with other topical corticosteroids.

INDICATIONS AND USAGE

Betamethasone Dipropionate Lotion USP, 0.05% is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.

CONTRAINDICATIONS

Betamethasone Dipropionate Lotion USP, 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in these preparations.

PRECAUTIONS

General -

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure (see **DOSAGE AND ADMINISTRATION**).

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. In an open-label pediatric study of 15 evaluable patients, of the 11 subjects who showed evidence of suppression, 6 subjects were tested 2 weeks after discontinuation of betamethasone dipropionate lotion 0.05%, and 4 of the 6 (67%) had complete recovery of HPA axis function. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see **PRECAUTIONS - Pediatric Use**).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for Patients -

This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive (see **DOSAGE AND ADMINISTRATION**).
4. Patients should report any signs of local adverse reactions.
5. Other corticosteroid-containing products should not be used with Betamethasone Dipropionate Lotion USP, 0.05% without first talking to your physician.

Laboratory Tests -

The following tests may be helpful in evaluating HPA axis suppression:

Urinary-free cortisol test
ACTH stimulation test

Carcinogenesis, Mutagenesis, Impairment of Fertility -

Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.

Betamethasone was negative in the bacterial mutagenicity assay (*Salmonella typhimurium* and *Escherichia coli*), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the *in-vitro* human lymphocyte chromosome aberration assay, and equivocal in the *in-vivo* mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone.

Reproductive studies with betamethasone dipropionate carried out in rabbits at doses of 1.0 mg/kg by the intramuscular route and in mice up to 33 mg/kg by the intramuscular route indicated no impairment of fertility except for dose-related increases in fetal resorption rates in both species. These doses are approximately 0.5 and 4 fold the estimated maximum human dose based on a mg/m² comparison, respectively.

Pregnancy:

Teratogenic Effects:

Pregnancy Category C -

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.

Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.03 fold the estimated maximum human dose based on a mg/m² comparison. The abnormalities observed included umbilical hernias, cephalocele and cleft palates.

Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers -

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities **not** likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are prescribed for a nursing woman.

Pediatric Use -

Use of Betamethasone Dipropionate Lotion USP, 0.05% in pediatric patients 12 years of age and younger is not recommended (see **CLINICAL PHARMACOLOGY** and **ADVERSE REACTIONS** sections). In an open-label study, 11 of 15 (73%) evaluable pediatric patients (aged 6 years-12 years old) using betamethasone dipropionate lotion 0.05% for treatment of atopic dermatitis for 2-3 weeks demonstrated adrenal suppression (see **CLINICAL PHARMACOLOGY - Pharmacokinetics**).

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently when betamethasone dipropionate lotion 0.05% is used as recommended in the **DOSAGE AND ADMINISTRATION** section. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

Adverse reactions reported to be possibly or probably related to treatment with betamethasone dipropionate lotion 0.05% during a pediatric study include: paresthesia (burning), erythema, erythematous rash, and dry skin. These adverse reactions each occurred in a different patient; 4% of the 25 patient population, respectively. An adverse reaction reported to be possibly or probably related to treatment in 2 different patients, 8%, of the 25 patients is puritis.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS**).

DOSAGE AND ADMINISTRATION

Apply a few drops of Betamethasone Dipropionate Lotion USP, 0.05% to the affected area and massage lightly until it disappears. Apply twice daily, in the morning and at night.

Betamethasone Dipropionate Lotion USP, 0.05% is not to be used with occlusive dressings.

HOW SUPPLIED

Betamethasone Dipropionate Lotion USP, 0.05% is available as follows:

60 mL bottle (NDC 45802-021-46)

Shake well before using.

STORAGE

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. **Protect from light and freezing. Store in carton until contents are used.**

Manufactured by Perrigo

Bronx, NY 10457

Distributed By
Perrigo[®]
Alligan, MI 49010 • www.perrigo.com

Rev. 08/12

: 0M300 RC J4

Principal Display Panel - Carton

Rx Only


Betamethasone Dipropionate Lotion USP, 0.05%

(Potency expressed as Betamethasone)

For Dermatologic Use Only

Not for Ophthalmic Use

NET CONTENTS 60 mL (56.2 g)



NDC 45802-021-46

**Betamethasone
Dipropionate Lotion USP,**

0.05%

(Potency expressed
as Betamethasone)

NET CONTENTS
60 mL (56.2 g)

Rx Only

NDC 45802-021-46

**Betamethasone
Dipropionate
Lotion USP,**

0.05%

(Potency expressed
as Betamethasone)

**For Dermatologic Use Only
Not for Ophthalmic Use**

NET CONTENTS
60 mL (56.2 g)

Perrigo®



Each gram contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a vehicle of carbomer homopolymer type B, isopropyl alcohol, and purified water. Sodium hydroxide is used to adjust pH.

USUAL DOSAGE: Apply a few drops of Betamethasone Dipropionate Lotion USP, 0.05% to the affected skin areas and massage lightly until it disappears. Apply twice daily, in the morning and at night. See package insert for full prescribing information and read accompanying directions carefully.

SHAKE WELL BEFORE USING.

WARNING: Keep out of reach of children.

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].
Protect from light and freezing.

For lot number and expiration date, see back of bottle or bottom of carton.

Manufactured By Perrigo
Bronx, NY 10457
Distributed By

Perrigo®

Allegan, MI 49010 • www.perrigo.com
Rev. 03/13

: 0M3A3 RC C4



Principal Display Panel - Label

Rx Only

Betamethasone Dipropionate Lotion USP, 0.05%

(Potency expressed as Betamethasone)

For Dermatologic Use Only

Not for Ophthalmic Use

NET CONTENTS 60 mL (56.2 g)

Rx Only

NDC 45802-021-46

**Betamethasone
Dipropionate
Lotion USP,
0.05%**

(Potency expressed as Betamethasone)

For Dermatologic Use Only
Not for Ophthalmic Use

NET CONTENTS
60 mL (56.2 g)

Perrigo®



: DM3A3 RC F4

Each gram contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a vehicle of carbomer homopolymer type B, isopropyl alcohol, and purified water. Sodium hydroxide is used to adjust pH.

USUAL DOSAGE: Apply a few drops of Betamethasone Dipropionate Lotion USP, 0.05% to the affected skin areas and massage lightly until it disappears. Apply twice daily, in the morning and at night. See package insert for full prescribing information and read accompanying directions carefully.

SHAKE WELL BEFORE USING.

WARNING: Keep out of reach of children.

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Protect from light and freezing.



Manufactured By
Perrigo
Bronx, NY 10457
Distributed By Perrigo
Allegan, MI 49010
www.perrigo.com



: 0M3A3 RC B4 Rev. 03/13

BETAMETHASONE DIPROPIONATE

betamethasone dipropionate lotion

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:45802-021
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BETAMETHASONE DIPROPIONATE (UNII: 826Y60901U) (BETAMETHASONE - UNII:9842X06Q6M)	BETAMETHASONE	0.5 mg in 1 g

Inactive Ingredients

Ingredient Name	Strength
ISOPROPYL ALCOHOL (UNII: ND2M416302)	
WATER (UNII: 059QF0KO0R)	
CARBOMER HOMO POLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: HHT01ZNK31)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:45802-021-46	1 in 1 CARTON		
1		56.2 g in 1 BOTTLE, PLASTIC		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA072538	06/30/2006	

Labeler - Perrigo New York Inc (078846912)

Revised: 10/2013

Perrigo New York Inc